Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib

BACKGROUND. A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients. The primary endpoint of progression-free survival (PFS) in patients whose tumors were human epiderma...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Sherrill, Beth, Amonkar, Mayur M., Sherif, Bintu, Maltzman, Julie, O'Rourke, Lisa, Johnston, Stephen
Формат: Artigo
Язык:Inglês
Опубликовано: AlphaMed Press 2010
Предметы:
Academia–Pharma Intersect
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228031/
https://ncbi.nlm.nih.gov/pubmed/20798196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0012
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы